Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20193291 | 0.87 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL22543158 | 0.87 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL1162069 | 0.84 | NOS3 (0.35) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL21473843 | 0.83 | — | — | |
| SCHEMBL20371710 | 0.83 | — | — | |
| SCHEMBL24002201 | 0.82 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL22764043 | 0.82 | CYP3A4 (0.33) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL179349 | 0.82 | CDK2 (0.44) | NOS3NOS1NOS2CYP3A4CYP2C19 | |
| SCHEMBL20675998 | 0.82 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL2760432 | 0.82 | NOS3 (0.48) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-20230346942-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023205475-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230295146-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 | THE UNIVERSITY OF ROCHESTER | 2023-09-21 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2007-08-16 | — | — | US | disclosed |
| US-7176312-B2 | Kinase inhibitor scaffolds and methods for their preparation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295146-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 | IRAK4, IRAK1, IRAK2 | NOS3 4432/4885NOS1 3511/4885NOS2 4538/4885 |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRM5, GRIK5, GRM1 | NOS3 4030/4885NOS1 4069/4885NOS2 3600/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | NOS3 2141/4885NOS1 3064/4885NOS2 2940/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | NOS3 3935/4885NOS1 4188/4885NOS2 4063/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | NOS3 1064/4885NOS1 1486/4885NOS2 1634/4885 |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | IL1B, IL1A, IL17A | NOS3 288/4885NOS1 128/4885NOS2 157/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | NOS3 77/4885NOS1 60/4885NOS2 84/4885 |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | MAP2K2, MAP2K1, MAP2K7 | NOS3 1464/4885NOS1 1430/4885NOS2 1514/4885 |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | NOS3 3167/4885NOS1 3280/4885NOS2 4113/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | NOS3 3556/4885NOS1 4204/4885NOS2 4342/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | NOS3 3046/4885NOS1 3353/4885NOS2 3250/4885 |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | NOS3 2033/4885NOS1 2701/4885NOS2 2362/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | NOS3 2156/4885NOS1 2576/4885NOS2 3027/4885 |
| US-20230346942-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CRY1, MAPT, PYGL | NOS3 2137/4885NOS1 2390/4885NOS2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.